Abstract: The present invention relates to a production method of a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole·n?H2O (wherein n? is about 0 to about 0.1) or a salt thereof, which characteristically includes crystallization from an organic solvent solution or suspension in which (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-benzimidazole·nH2O (wherein n is about 0.1 to about 1.0) or a salt thereof has been dissolved or suspended, and the like, and provides a convenient method for efficiently producing an optically active sulfoxide derivative having an extremely high enantiomer excess in high yield at an industrial large scale.

Abstract: The present invention relates to a production method of a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole.n?H2O (wherein n? is about 0 to about 0.1) or a salt thereof, which characteristically includes crystallization from an organic solvent solution or suspension in which (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-benzimidazole.nH2O (wherein n is about 0.1 to about 1.0) or a salt thereof has been dissolved or suspended, and the like, and provides a convenient method for efficiently producing an optically active sulfoxide derivative having an extremely high enantiomer excess in high yield at an industrial large scale.

Abstract: Conventional oligonucleotides are opened at both ends and thereby unstable. The stability of them against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes toxicity. The present invention provides oligonucleotides and medicaments in which these problems are improved. That is, it provides a staple oligonucleotides and medicaments containing the same as the active ingredient. Specifically, it provides transcription factor inhibitors, antisense oligonucleotides and siRNAs. More specifically, it provides agents for preventing, treating or improving inflammation, autoimmune diseases, central diseases, reperfusion injury in ischaemic diseases, worsened prognosis after organ transplantation or organ surgery, or restenosis after PTCA.

Abstract: A process for producing crystals of 2-ethoxy-1-[[2?-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimdazole-7-carboxylic acid (compound (I)), characterized by dissolving or suspending the compound (I) or a salt thereof in a solvent comprising an aprotic polar solvent and crystallizing it. By the process, the contaminants which are contained in the compound (I) or its salt and are difficult to remove, such as tin compounds, analogues of the compound (I), and a residual organic solvent, can be easily removed. Crystals of the compound (I) can be efficiently and easily mass-produced in high yield on an industrial scale.

Abstract: The present invention relates to a crystal oscillator circuit in which the output level is maintained to prevent changes in oscillation frequency due to variations in power voltage. This crystal oscillator circuit comprises a resonance circuit formed of a crystal oscillator (which acts as an inductor component) and dividing capacitors, an oscillation amplifier formed of ECL circuitry driven by a power voltage connected to the resonance circuit, and a pull-down resistor between an output terminal of the ECL circuit and ground. The pull-down resistor acts as serially-connected dividing resistors and also a bias capacitor is provided between a connection point between those dividing resistors and ground. The present invention also relates to a frequency-switching oscillator having a simple circuit design and a small number of components.

Abstract: A process for producing crystals of 2-ethoxy-1-[[2?-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimdazole-7-carboxylic acid (compound (I)), characterized by dissolving or suspending the compound (I) or a salt thereof in a solvent comprising an aprotic polar solvent and crystallizing it. By the process, the contaminants which are contained in the compound (I) or its salt and are difficult to remove, such as tin compounds, analogues of the compound (I), and a residual organic solvent, can be easily removed. Crystals of the compound (I) can be efficiently and easily mass-produced in high yield on an industrial scale.

Abstract: It is intended to provide a process for producing unstable amorphous benzimidazole compounds having a proton pump inhibitor function, and stable solid preparations for medicinal use containing these compounds which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorganic salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer.

Abstract: The present invention relates to a production method of an optically active form of a compound represented by formula (II) wherein ring A is a benzene ring optionally having substituent(s); R1 is H, a hydrocarbon group optionally having substituent(s), an acyl group or an acyloxy group; R2, R3 and R4 are each H, an alkyl group optionally having substituent(s), an alkoxy group optionally having substituent(s) or an amino group optionally having substituent(s); X is N or CH; Y is N or CH; and * shows an asymmetric center, or a salt thereof, which includes reacting a compound represented by the formula (I) wherein each symbol is as defined above, or a salt thereof, with an excess amount of an oxidizing agent in the presence of a catalyst for asymmetric induction, and provides an efficient production method of an optically active sulfoxide derivative in high yield on an industrial large scale by a convenient method, while achieving an extremely high enantiomer excess.

Abstract: A quartz crystal oscillator in which phase noise is reduced includes: a resonance circuit having a quartz crystal unit and a split capacitor connected to the crystal unit; a transistor for oscillation having its base connected to the node of the crystal unit and the split capacitor; an output line for connecting the mutual node of the split capacitor to the emitter of the transistor; a quartz crystal resonator that is inserted in the output line; and a temperature compensation mechanism for compensating the frequency-temperature characteristics of both the crystal unit and the crystal resonator.

Abstract: An object of the invention is to provide an oscillator circuit employing an ECL to prevent variation in oscillation frequency and oscillation gain, and to simplify design. The construction is such that in a crystal oscillator circuit comprising: a resonance circuit consisting of a crystal element as an inductor component and a dividing capacitor, an oscillation amplifier comprising an ECL driven by a power supply voltage connected to the resonance circuit, and a pull-down resistor between an output terminal of the ECL and ground, there is provided an AC impedance amplifier circuit connected in series to the pull-down resistor.

Abstract: A process for easily and industrially advantageously producing both a tricyclic fused heterocyclic derivative having acetylcholinesterase inhibitory activity and an intermediate for the derivative. The process for producing the target compounds comprises the following reaction.

Abstract: The present invention relates to a crystal oscillator circuit in which the output level is maintained to prevent changes in oscillation frequency due to variations in power voltage. This crystal oscillator circuit comprises a resonance circuit formed of a crystal oscillator (which acts as an inductor component) and dividing capacitors, an oscillation amplifier formed of ECL circuitry driven by a power voltage connected to the resonance circuit, and a pull-down resistor between an output terminal of the ECL circuit and ground. The pull-down resistor acts as serially-connected dividing resistors and also a bias capacitor is provided between a connection point between those dividing resistors and ground. The present invention also relates to a frequency-switching oscillator having a simple circuit design and a small number of components.

Abstract: A method for obtaining and issuing key information of a collection/delivery box device, which enables issuance of high security key information to be used for releasing a lock on the collection/delivery box device and obtainment by a collection/delivery company of the key information with the high security being ensured is provided.

Abstract: A process for producing crystals of 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimdazole-7-carboxylic acid (compound (I)), characterized by dissolving or suspending the compound (I) or a salt thereof in a solvent comprising an aprotic polar solvent and crystallizing it. By the process, the contaminants which are contained in the compound (I) or its salt and are difficult to remove, such as tin compounds, analogues of the compound (I), and a residual organic solvent, can be easily removed. Crystals of the compound (I) can be efficiently and easily mass-produced in high yield on an industrial scale.

Abstract: In an encoding method of moving pictures which generates a predictive picture for a current picture based on a reference picture and a motion vector, a macroblock is divided into subblocks. In each of the plurality of subblocks, an initial value of the motion vector is set and an evaluated value E on a difference between the current picture and the reference picture is calculated along a steepest descent direction to determine the minimum value. Then, the smallest evaluated value is selected among the minimum values obtained on the plurality of subblocks to determine the motion vector based on the pixel position of the smallest value.

Abstract: The present invention relates to a production method of a crystal of (R)-lansoprazole or (S)-lansoprazole, which includes crystallization at a temperature of about 0° C. to about 35° C. from a C1-4 alkyl acetate solution containing (R)-lansoprazole or (S)-lansoprazole at a concentration of about 0.1 g/mL to about 0.5 g/mL and the like. According to the production method of the present invention, a crystal of (R)-lansoprazole or (S)-lansoprazole superior in preservation stability can be produced efficiently on an industrial large scale.

Abstract: A process for easily and industrially advantageously producing both a tricyclic fused heterocyclic derivative having acetylcholinesterase inhibitory activity and an intermediate for the derivative. The process for producing the target compounds comprises the following reaction.

Abstract: A sodium salt, magnesium salt, lithium salt, potassium salt, calcium salt or barium salt of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole, and a pharmaceutical composition comprising the salt. The novel salt is useful as an excellent antiulcer agent.

Abstract: The present invention relates to a production method of an optically active form of a compound represented by formula (II) 1

Abstract: The present invention relates to a production method of a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole.n′H2O (wherein n′ is about 0 to about 0.1) or a salt thereof, which characteristically includes crystallization from an organic solvent solution or suspension in which (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-benzimidazole.nH2O (wherein n is about 0.1 to about 1.0) or a salt thereof has been dissolved or suspended, and the like, and provides a convenient method for efficiently producing an optically active sulfoxide derivative having an extremely high enantiomer excess in high yield at an industrial large scale.